Abstract 16956: Trends in Lipid Screening Among Adults in an Integrated Health Care Delivery System, 2009 to 2015
Background: Lipid screening (LS) is needed to determine eligibility for statins and other cardiovascular (CV) risk reduction interventions. Currently, there are no publicly reported metrics on LS in the general population. Trends in LS overall and in those with atherosclerotic CV disease (ASCVD) and diabetes mellitus (DM) were investigated in a large, integrated health care delivery system.
Methods: Individuals aged ≥20 years from 10/1/09 through 09/30/15 were identified and temporal trends in LS were examined. LS was reported for each year as a proportion of the eligible members aged 20-39 years who had ever been screened and those aged ≥40 years who had been screened in the preceding 6 years. Baseline characteristics including demographics, comorbid conditions, and health care utilization were extracted from electronic health records. Trends in LS were analyzed by age group, gender, and ASCVD and DM status. Cochran-Armitage tests were used to assess temporal trends.
Results: Over 2 million individuals were included each year: 5-6% had ASCVD, 7-8% had DM without ASCVD, and 87% had neither condition. For the entire population, LS increased from 79.8% in 2009 to 82.6% in 2015 (p <.0001). Among those with ASCVD or DM, LS rates were 99% across all years, including men and women. Among those without ASCVD or DM, LS increased from 76.9% in 2009 to 80.0% in 2015 (p <.0001). LS rates were higher among women compared to men and were lowest among those aged 20-39 years (Figure). Overall, those who were not screened were younger, had fewer comorbid conditions and had lower health care utilization in the prior 12 months.
Conclusions: In this integrated health care delivery system, we found consistently very high rates of LS among those with ASCVD or DM. In those without ASCVD or DM, screening rates increased, however, there is room for further improvement, especially among those under age 40. Higher rates of LS may facilitate CV risk reduction interventions and therapies.
Author Disclosures: K. Reynolds: Research Grant; Significant; Regeneron/Sanofi, Amgen, Inc.. T.N. Harrison: None. S. Chang: None. J.Y. Hsu: None. D.S. Ling-Grant: None. T.C. Cheetham: Research Grant; Modest; Regeneron/Sanofi. Research Grant; Significant; BMS. R. Wei: None. S.H. Boklage: Employment; Significant; Regeneron Pharmaceuticals, Inc.. Ownership Interest; Significant; Regeneron Pharmaceuticals, Inc. V. Romo-LeTourneau: Employment; Significant; Sanofi. Ownership Interest; Significant; Sanofi. R.D. Scott: Research Grant; Modest; Regeneron/Sanofi, Novartis.
- © 2016 by American Heart Association, Inc.